Company News

2023-03-24
ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
On March 24, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the patent applications for their independently developed products, IMM47 (CD2
View more
2023-03-23
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the phase I clinical trial of IMM2520, a bispecific antibody-receptor fusion protein that targets
View more
2023-03-21
ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
On March 21, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the company will present the preclinical research data of IMM47 (CD24 antibody
View more
2023-03-17
ImmuneOnco Biopharmaceuticals officially launches phase IIa clinical trial targeting late-stage follicular lymphoma (FL) with IMM0306
On March 17, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that its self-developed bispecific antibody-receptor recombinant protein drug targe
View more
2023-03-15
ImmuneOnco’s Phase Ib/II clinical study of IMM27M combined with PD-1 antibody in patients with advanced solid tumors has been approved by the National Medical Products Administration (NMPA)
On March 15, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase Ib/II clinical study of the Company's self-developed ADCC-enhanc
View more
2023-03-11
Phase II clinical trial of ImmuneOnco Biopharmaceuticals IMM0306 completes first subject enrollment for dosing
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase II clinical trial of ImmuneOnco Biopharmaceuticals bispecific antibody-receptor re
View more
Total 55 12345678910
0.087946s